BIGBEAR
PHARMACEUTICAL
Cabozantinib is an oral multi-targeted tyrosine kinase inhibitor with broad-spectrum anticancer activity.
AuthenticGuaranteeFast DeliveryPrivacy On March 26, 2025, Exelixis announced that the U.S. Food and Drug Administration (FDA) has approved cabozantinib (Cabometyx) for the treatment of two ···【More】
Update: 05 Mar,2026Source: BigbearViews: 130
On March 26, 2025, Exelixis announced that the U.S. Food and Drug Administration (FDA) has approved cabozantinib (Cabometyx) for the treatment of two ···【More】
Update: 28 Feb,2026Source: BigbearViews: 123
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos
